Mechanisms Involved in Nicotinic Acetylcholine Receptor-Induced Neurotransmitter Release from Sympathetic Nerve Terminals in the Mouse Vas Deferens by Williams, Damian J. et al.
Mechanisms Involved in Nicotinic Acetylcholine
Receptor-Induced Neurotransmitter Release from
Sympathetic Nerve Terminals in the Mouse Vas Deferens
Damian J. Williams
1, Peter Sidaway
2, Thomas C. Cunnane
1, Keith L. Brain
2*
1Department of Pharmacology, University of Oxford, Mansfield Road, Oxford, United Kingdom, 2Neuropharmacology and Neurobiology, School of Clinical and
Experimental Medicine, University of Birmingham, Birmingham, United Kingdom
Abstract
Prejunctional nicotinic acetylcholine receptors (nAChRs) amplify postganglionic sympathetic neurotransmission, and there
are indications that intraterminal Ca
2+ stores might be involved. However, the mechanisms by which nAChR activation
stimulates neurotransmitter release at such junctions is unknown. Rapid local delivery (picospritzing) of the nAChR agonist
epibatidine was combined with intracellular sharp microelectrode recording to monitor spontaneous and field-stimulation-
evoked neurotransmitter release from sympathetic nerve terminals in the mouse isolated vas deferens. Locally applied
epibatidine (1 mM) produced ‘epibatidine-induced depolarisations’ (EIDs) that were similar in shape to spontaneous
excitatory junction potentials (SEJPs) and were abolished by nonselective nAChR antagonists and the purinergic
desensitizing agonist a,b-methylene ATP. The amplitude distribution of EIDs was only slightly shifted towards lower
amplitudes by the selective a7 nAChR antagonists a-bungarotoxin and methyllcaconitine, the voltage-gated Na
+ channel
blocker tetrodotoxin or by blocking voltage-gated Ca
2+ channels with Cd
2+. Lowering the extracellular Ca
2+ concentration
reduced the frequency of EIDs by 69%, but more surprisingly, the Ca
2+-induced Ca
2+ release blocker ryanodine greatly
decreased the amplitude (by 41%) and the frequency of EIDs by 36%. Ryanodine had no effect on electrically-evoked
neurotransmitter release, paired-pulse facilitation, SEJP frequency, SEJP amplitude or SEJP amplitude distribution. These
results show that activation of non-a7 nAChRs on sympathetic postganglionic nerve terminals induces high-amplitude
junctional potentials that are argued to represent multipacketed neurotransmitter release synchronized by intraterminal
Ca
2+-induced Ca
2+ release, triggered by Ca
2+ influx directly through the nAChR. This nAChR-induced neurotransmitter
release can be targeted pharmacologically without affecting spontaneous or electrically-evoked neurotransmitter release.
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Introduction
Activation of nAChRs located on nerve terminals is an important
mechanism that modulates neurotransmitter release. Prejunctional
nAChRs are involved in fundamental aspects of synaptic plasticity
[1] and alterations of nAChR function have been implicated in a
number of disease states including Parkinson’s Disease, Alzheimer’s
Disease and drug dependence [2,3]. Activation of nAChRs located
on postganglionic sympathetic nerve terminals is associated with the
pathological effects of smoking on the heart [4]. Most research on
the mechanism of nAChR-induced modulation of neurotransmitter
release has been carried out in the CNS, where a number of
mechanisms have been proposed including initiation of action
potentials [5], activation of voltage-gated Ca
2+ channels [VGCCs;
6], direct influx of Ca
2+ through the nAChR [7], mobilisation of
intraneuronal Ca
2+ stores [8], an unidentified NO-dependent
process [9] and a number of Ca
2+-dependent cellular processes,
such as recruitment of protein kinases [see 10].
The rodent vas deferens is richly innervated by sympathetic
nerves [11] and provides a model system to study sympathetic
neurotransmission. Previous studies in the rodent vas deferens
have shown that activation of nAChRs can both induce
neurotransmitter release and potentiate electrically-evoked neuro-
transmitter release [12,13,14,15], although the precise mechanism
of the modulation remains unknown.
The aim of the present inquiry was to investigate the
mechanism of nAChR-induced neurotransmitter release in mouse
vas deferens using the potent nAChR agonist epibatidine [16]. A
method of rapid local application of epibatidine was used to avoid
variability in response, likely caused by desensitisation of nAChRs,
that occurs when using a slower, bath-applied approach [15]. We
show that the majority of epibatidine-induce neurotransmitter
release occurs following influx of Ca
2+ directly through non-a7
nAChRs. This Ca
2+ influx triggers Ca
2+-induced Ca
2+ release
(CICR) from intraterminal stores, which leads to further
neurotransmitter release.
Materials and Methods
Ethics statement
All experiments were carried out in accordance with the
guidelines of the UK Animal (Scientific Procedures) Act 1986. As
PLoS ONE | www.plosone.org 1 December 2011 | Volume 6 | Issue 12 | e29209these experiments did not involve regulated procedures (as defined
by the Act described above), institutional review board or ethics
committee approval was not required. However, independent
academic oversight was provided by the academic in charge of
animal use, Dr S. Totterdell (Department of Pharmacology,
Oxford).
Tissue preparation
Vasa deferentia were removed from 8–12 week-old Balb/c mice
which were killed by cervical dislocation. The prostatic quarter of
each vas deferens was removed to ensure that no sympathetic
ganglia were present in the preparation. The bathing physiological
saline solution (PSS) contained (mM): 118.4 NaCl, 25.0 NaHCO3,
1.13 NaH2PO4, 1.8 CaCl2, 4.7 KCl, 1.3 MgCl2 and 11.1 glucose.
The solution was gassed with a mixture of 95% O2 and 5% CO2
to pH 7.4 and maintained at a temperature of 35–37uC.
Electrophysiological studies
Conventional intracellular recording techniques were used to
monitor membrane potentials in individual smooth muscle cells.
The vas deferens was carefully pinned to the Sylgard (Dow-
Corning, UK) covered base of a 5 ml Perspex organ chamber
perfused with PSS at a rate of 2 ml per minute. The membrane
potential of individual smooth muscle cells close to the surface of
the vas deferens was measured using a sharp microelectrode.
Microelectrodes were connected by an Ag/AgCl wire to the input
headstage of an Axoclamp 2B (Axon Instruments, USA). The data
were digitized (1 kHz sampling) using a PowerLab 4SP (AD
Instruments, UK) and recorded on a G4 computer (Apple) with
Chart 5 software (AD Instruments, UK). Microelectrodes were
fabricated from borosilicate glass tubing containing an inner glass
filament (outer diameter 1.5 mm, inner diameter 0.86 mm; Clark
Electromedical, USA) using a Flaming-Brown P87 electrode puller
(Sutter Instruments, USA). The microelectrodes were filled with
5 M potassium acetate and had tip resistances of 30 to 90 MV.
Spontaneous excitatory junction potentials (SEJPs) and epiba-
tidine-induced depolarisations (EIDs) were automatically detected
using the ‘template’ function of Chart 5. This function uses a
correlation algorithm to compare the trace with a selected typical
SEJP in a given experiment. The template was redefined for each
cell. The algorithm applies a rolling normalisation so that the
correlation coefficient was independent of the baseline and
amplitude of any SEJP/EID. Trace segments with correlation
coefficients of .0.8 (where 1 is an exact match) and amplitudes of
.2 mV were counted as SEJPs/EIDs; below an amplitude of
2 mV, SEJPs/EIDs were difficult to distinguish from baseline
noise.
Electrical stimuli (pulse width 0.1 ms, 15 V amplitude) were
delivered through a pair of platinum electrodes positioned around
the prostatic end of the vas deferens. The stimuli were generated
by a digital stimulator (Applegarth Instruments, Oxford) coupled
to an optically-isolated stimulus unit. Excitatory junction potential
(EJP) amplitude was measured from the resting membrane
potential (RMP) to the peak amplitude following field stimulation.
The RMP was calculated by averaging the membrane potential
100 ms prior to stimulation.
Rapid application of epibatidine
Working epibatidine solution (1 mM) was prepared in PSS and
passed through a 0.22 mM nitrocellulose filter (Millipore) to
remove any particulate matter before loading into a micropipette.
The micropipette was positioned close to the surface of the vas
deferens immediately adjacent to the intracellular microelectrode.
The micropipettes were fabricated using a Flaming-Brown P87
electrode puller. Epibatidine was ejected from the tip of the
micropipette by a brief (50–200 ms) pulse of compressed nitrogen
gas (4 MPa) controlled by a Picospritzer (General Valve Corp.,
USA). The volume of the drug ejected from the micropipette was
#100 pl. Ejection of PSS alone had no detectable effects.
Data analysis
Data were analysed using Prism 4 software (GraphPad, USA)
and Mini Analysis Program (Synaptosoft, USA). When measuring
SEJP repolarization time course, the time taken for the membrane
potential to recover by a factor of 1/e from 90% of the peak
amplitude was measured using the ‘Peak Parameters’ function of
Chart (ADInstruments, Oxford, UK) and excluding events where
two peaks occurred with the measurement window (of 100 ms). In
order to avoid template matching biasing the shape of the
repolarisation, EID/SEJPs were automatically detected by detect-
ing a local peak in the dV/dt above 200 mV.s
21 (i.e. only on the
basis of the rising phase). As the time course varied amongst
preparations, a 2-way ANOVA was used to separate the effect of
inter-preparation variation from epibatidine-induced variation.
For analysis of EID/SEJP amplitude distributions, Kolmogorov-
Smirnov tests were used. Elsewhere, a paired or unpaired (as
appropriate) Student’s t-tests were applied to determine statistical
significance. A P,0.05 was considered significant.
Drugs
Stock solutions of d-tubocurarine (chloride hydrate), hexame-
thonium (chloride), a- bungarotoxin, a,b-methylene ATP (lithium
salt), tetrodotoxin (citrate) and CdCl2 were dissolved in distilled
water. Epibatidine (hydrochloride) and ryanodine were dissolved
in DMSO. The maximum final concentration of DMSO was
0.1%. All solutions were prepared and aliquotted before storing at
220uC. All drugs passed through a maximum of one freeze-thaw
cycle. Epibatidine, ryanodine, tetrodotoxin and a-bungarotoxin
were obtained from Tocris, UK; all other drugs were obtained
from Sigma-Aldrich, UK. The drug vehicle alone was without
effect.
Results
The effect of locally-applied epibatidine on SEJPs and
EJPs
The resting potential of smooth muscle cells in the mouse vas
deferens was monitored by intracellular recording before and
during the focal application of 1 mM epibatidine from a
micropipette positioned above the surface of the tissue, adjacent
to the recording microelectrode. Multiple epibatidine responses
could be recorded from a single preparation by repositioning the
electrode and micropipette to different areas of the vas deferens for
each epibatidine application.
Following local application of 1 mM epibatidine, a large number
of rapid depolarisations of the membrane occurred, similar in
appearance to SEJPs (Fig. 1Ai; for a different example, shown at
higher resolution, see Fig. S1). Just like SEJPs, these depolarisa-
tions had a rapid rising phase, followed by a slower repolarization
(fitted time constant of repolarisation of control SEJPs: 25.8 [22.1–
31.6] ms; following epibatidine: 26.5 [20.2–31.4] ms; median
[inter-quartile range]; n=418 events, number of cells (nc)=12,
number of vasa deferentia (nv)=3; 2-way ANOVA P=0.47).
Despite such similarities, these events will be referred to as
epibatidine-induced depolarisations (EIDs) to distinguish them
from true spontaneous neurotransmitter release (SEJPs). EIDs
occurred in 7263% of smooth muscle cells following the local
application of epibatidine. In 2462% of cells, epibatidine had no
Epibatidine-Induced Neurotransmitter Release
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microelectrode was displaced from the cell and no useful data were
obtained (nc total=330; nv total=54). In the cells that responded to
epibatidine, the frequency of EID occurrence reached a maximum
at around 6 s after epibatidine application and then returned back
towards the control level (Fig. 1B). The response to epibatidine was
somewhat variable (see Fig. S2 for example traces): the mean
frequency of EIDs in the 20 s following epibatidine was 1.99 Hz
with a standard deviation of 0.95 Hz (nc=227). Experiments were
attempted using a lower concentration of epibatidine (100 nM) but
no consistent effects were observed (nv=3; results not shown).
The effect of rapid, locally-applied epibatidine on electrically-
evoked neurotransmitter release was also investigated. EJPs were
evoked at a frequency of 0.33 Hz by single field stimuli. The mean
EJP amplitude in the 20 s immediately following epibatidine
application was 11866% of the mean control EJP amplitude
measured in the 20 s prior to epibatidine addition (Fig. 1C;
P,0.05, paired Student’s t-test; nc=18, nv=4). The variability of
EJP amplitude was not significantly different after epibatidine
addition (control mean EJP variance=3268m V
2, epibatidine
mean EJP variance=40610 mV
2; P=0.32, paired Student’s t-
test). These results suggested that rapidly applied epibatidine can
cause a small but significant increase in electrically-evoked
neurotransmitter release.
To determine the mechanism of EIDs, a number of single
epibatidine applications and recordings were made from different
areas of the same preparation in the presence and absence of a
pharmacological agent. A series of time controls were carried out
to ensure that any changes to the properties of EIDs were not
caused by nAChR desensitization or a run down in response that
may have occurred during the period of drug incubation. For these
experiments, a series of control applications of epibatidine were
carried out and, after 60 minutes in the absence of epibatidine-
application, a second series of epibatidine application and
recordings were made (Fig. 2Ai). There was no significant
difference between the mean fraction of cells that responded to
the initial application of epibatidine (7065%) and the fraction of
cells that responded to epibatidine after 60 minutes (6766%;
P=0.84; nc control=44, nc time control=46, nv=6; Fig. 2Bi). In
the responding cells, there was no significant change in EID
frequency of occurrence between control epibatidine applications
and time controls (control frequency=1.2060.09 Hz, time
control frequency=1.1660.09 Hz; P=0.77, nc control=29, nc
time control=30, nv=6; Fig. 2Bii), nor mean amplitude
(10.160.6 mV compared with 9.760.5 mV; P=0.65; Fig. 2Biii),
nor amplitude distribution (P=0.10, Fig. 2Ci).
The effect of nAChR antagonists on EIDs
To confirm that EIDs occurred as a result of activation of
nAChRs, experiments were carried out in the presence of nAChR
antagonists. Following exposure to the nonspecific, noncompeti-
tive neuronal nAChR antagonist hexamethonium (100 mM) for
60 minutes, EIDs were abolished: 63612% of the cells responded
to 1 mM epibatidine in the control, and following exposure to
hexamethonium, no cells responded to epibatidine (nc control=35,
nc hexamethonium=40, nv=4; Fig. 2Aii, 2Bi). In the presence of
the non-specific competitive nAChR antagonist d-tubocurarine
Figure 1. The effect of rapid application of epibatidine (1 mM)
on the membrane potential of smooth muscle cells in mouse
isolated vas deferens. (a) Typical traces showing membrane
potentials before and after the local application of 1 mM epibatidine.
RMPs were between 270 and 280 mV. (i) Most (7163%) cells displayed
clear depolarisations following epibatidine application. These depolar-
isations were termed ‘epibatidine-induced depolarisations’ (EIDs) (ii) In
2562% of cells, application of epibatidine had no observable effect. The
time of epibatidine application is marked with an arrow (b) Graph
showing the effect of local application of epibatidine on the frequency
of SEJP/EID occurrence. The points show mean 6 s.e.m. of the
frequency of junction potentials collected in 2 s bins. Only data from
cells that responded to epibatidine were plotted (nc=227). (c) The
effect of local application of epibatidine on electrically-evoked
neurotransmitter release. A representative membrane potential trace
showing EJPs before and after epibatidine application. EJPs were
evoked by electrical stimulation at a frequency of 0.33 Hz.
doi:10.1371/journal.pone.0029209.g001
Epibatidine-Induced Neurotransmitter Release
PLoS ONE | www.plosone.org 3 December 2011 | Volume 6 | Issue 12 | e29209Figure 2. The effect of nAChR antagonists on EIDs. A) Representative traces of smooth muscle cells showing local application of epibatidine in
presence of nAChR antagonists for 60 minutes. (i) 60 minute temporal control (ii) hexamethonium (Hex; 100 mM) (iii) or d-tubocurarine (100 mM; d-
TC) (iv) a-bungarotoxin (a-BTX; 100 nM) (vi) methyllycaconitine (20 nM; MLA). RMPs were between 270 and 280 mV. B) Quantification of the effects
of nAChR antagonists on EIDs. In each chart, two bars are shown for each drug: control epibatidine applications (outline) and epibatidine applications
following treatment (filled). Each bar represents the mean 6 s.e.m. (i) bar chart showing the mean percentage of cells that responded to the local
application of epibatidine. (ii) A bar chart showing the mean frequency of EID occurrence in cells which responded to epibatidine. (iii) A bar chart
showing the mean amplitude of EIDs in responding cells. C) Cumulative frequency plots of EID amplitudes in (i) time control experiments and in the
presence of (ii) a-BTX (iii) MLA. There was no significant change in the EID amplitude distribution in the time control experiments. In the a-BTX
experiments, there was a significant shift to smaller amplitudes.
doi:10.1371/journal.pone.0029209.g002
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control=40, nc d-tubocurarine=51, nv=5; Fig. 2Aiii, 2Bi,
responding cell not shown).
In order to determine the role of nAChR containing a7-
subunits in EID generation, experiments were carried out in the
presence of 100 nM a-bungarotoxin (a-BTX) or 20 nM methyll-
caconitine (MLA). In the presence of a-BTX (100 nM) for
60 minutes (Fig. 2iv), there was no significant change in the
proportion of cells that responded to epibatidine (6766% in the
controls, 7268% in the presence of a-BTX; P=0.73; nc
control=46, nc a-BTX=45, nv=5; Fig. 2Bi). a-BTX had no
significant effect on the frequency of occurrence of EIDs
(0.9060.08 Hz in the control, 0.9360.07 Hz in the presence of
a-BTX; P=0.73; nc control=30, nc a-BTX=31, nv=5, Fig. 2Bii).
The average amplitude of EIDs in the control was 9.760.7 mV
and 8.260.5 mV in the presence of a-BTX (P=0.05; Fig. 2Biii).
There was a significant shift in EID amplitude distribution to
smaller amplitudes in the presence of a-BTX (P,0.05; Fig. 2Cii),
but there was no obvious change in the time course of EID
occurrence (Fig. S3). Following exposure of the vasa deferentia to
20 nM MLA for 60 minutes (Fig. 2Av), there was no significant
change in the proportion of cells (7663% in the controls, 8462%
in the presence of MLA; P=0.15; nc control=30, nc MLA=30,
nv=5; Fig. 2Bi). MLA had no significant effect on the frequency of
occurrence of EIDs (1.9160.17 Hz in the control, 1.9060.13 Hz
in the presence of MLA; P=0.93; nc control=30, nc MLA=31,
nv=5, Fig. 2Bii). The average amplitude of EIDs in the control
was 8.360.4 mV and 7.660.4 mV in the presence of MLA
(P=0.25; Fig. 2Biii). There was a significant shift in EID
amplitude distribution to smaller amplitudes in the presence of
MLA (P,0.05; Fig. 2Ciii). These findings suggest that the majority
of EIDs occur as a result of activation of nAChRs that do not
contain a7 subunits.
The effects of a,b-methylene ATP, tetrodotoxin, Cd
2+ and
reduced extracellular Ca
2+ concentration on EIDs
From the above results, it is likely that the EIDs result from
activation of prejunctional nAChRs causing neuronal release of
ATP. To confirm that the depolarizations were due to activation
of postjunctional P2X1 receptors, preparations were incubated
with a,b-methylene ATP (a,b-MeATP) for 60 minutes. In vasa
deferentia exposed to 1 mM a,b-MeATP, EJPs were abolished
(Fig. 3Ai and 3Aii). EIDs were also abolished by a,b-MeATP: in
control recordings in the absence of a,b-MeATP, 80613% of the
cells responded to epibatidine, whereas in the presence of a,b-
MeATP, no cells responded (nc control=24, nc a,b-MeATP=27,
nv=3; Fig. 3Aiii and 3Ei).
A potential mechanism of epibatidine-induced neurotransmitter
release involves the generation of neuronal action potentials. In
this mechanism, depolarisation of the neuron caused by influx of
cations through nAChRs leads to the activation of voltage-gated
Na
+ channels. The resulting action potentials cause neurotrans-
mitter release. To investigate this mechanism, experiments were
carried out in the presence of the voltage-gated Na
+ channel
blocker tetrodotoxin (TTX), which blocks neuronal action
potential initiation and propagation in the rodent vas deferens
[17]. Exposure of vasa deferentia to 300 nM TTX for one hour
abolished EJPs (Fig. 3Bi) but EIDs could still be elicited (Fig. 3Bii).
The proportion of cells that responded to epibatidine in the
presence of TTX (63611%) was not significantly different to the
proportion of cells that responded in the control (5668%;
P=0.29; nc control=53, nc TTX=61, nv=6; Fig. 3Ei). The mean
frequency of EIDs was not significantly changed between control
applications of epibatidine and applications in the presence of
TTX (control frequency=1.7460.12 Hz, TTX frequen-
cy=1.5560.09 Hz, P=0.22, nc control=29 nc TTX=38, nv=6;
Fig. 3Eii). In the presence of TTX, there was a small but
significant decrease in the mean amplitude of EIDs: from
10.560.7 mV in the control, to 8.760.5 mV in the presence of
TTX (P,0.05; Fig. 3Eiii). There was also a significant change in
EID amplitude distribution in the presence of TTX (P,0.05,
Fig. 3Fi), with a decrease in the proportion of higher-amplitude
EIDs. These results indicated that the majority of EID occurred
through a mechanism independent of voltage-gated Na
+ channel
activation.
EIDs may occur as a result of nerve terminal depolarization that
not does require voltage–gated Na
+ channel activation: influx of
cations through the nAChR may cause a local depolarization
which results in the direct activation of voltage-gated Ca
2+
channels (VGCCs). To investigate the role of VGCCs in the
generation of EIDs, experiments were carried out in the presence
of Cd
2+, a non-specific VGCC blocker. Following exposure to
100 mMC d
2+ for 1 hour, EJPs were blocked (Fig. 3Ci), but EIDs
could still be induced (Fig. 3Cii). The proportion of cells that
responded to epibatidine in the presence of Cd
2+ was unchanged
from control applications (control=5667%, Cd
2+=64610%;
P=0.53; nc control=57, nc Cd
2+=50, nv=5; Fig. 3Ei). The
frequency of EID occurrence was not significantly changed from
control in the presence of Cd
2+: control EID frequency was
1.960.1 Hz, and in the presence of Cd
2+, the frequency of EIDs
was 1.760.1 Hz (P=0.48; nc control=28, nc Cd
2+=30,
nv=5 Fig. 3Eii). There was a small but significant decrease in
the mean amplitude of EIDs in the presence of Cd
2+ (control
amplitude=10.260.6 mV, CdCl2 amplitude=8.560.5 mV;
P,0.05; Fig. 3Eiii). The EID amplitude distribution was
significantly shifted to smaller amplitudes in the presence of
Cd
2+, compared with controls (P,0.05, Fig. 3Fii).
It has previously been demonstrated that direct influx of Ca
2+
through nAChRs into nerve terminals is sufficient to trigger
neurotransmitter release [7]. To investigate the role of extracel-
lular Ca
2+ on the generation of EIDs, experiments were carried
out in PSS with reduced Ca
2+ concentration. An extracellular
Ca
2+ concentration ([Ca
2+]o) of 0.6 mM was chosen because at
lower concentrations the resting membrane potential became
unstable and it was very difficult to obtain recordings. After
incubation of the vasa deferentia in 0.6 mM [Ca
2+]o PSS for
60 minutes, EJP amplitude was reduced (Fig. 3Di) and the
response to epibatidine application was diminished (Fig. 3Dii). The
mean proportion of cells that responded to epibatidine in the
presence of 0.6 mM [Ca
2+]o (34621%) was significantly smaller
than the proportion of cells that responded in the control (7969%;
P,0.05; nc control=, nc 0.6 mM [Ca
2+]o=61, nv=6; Fig. 3Ei).
The mean frequency of EIDs was significantly reduced in the
presence of 0.6 mM [Ca
2+]o (control frequency=1.0860.12 Hz,
0.6 mM [Ca
2+]o frequency=0.3360.06 Hz; P,0.05; nc con-
trol=30, nc 0.6 mM [Ca
2+]o=30, nv=5; Fig. 3Eii). In the
presence of 0.6 mM [Ca
2+]o, there was no statistically significant
change in the mean amplitude of epibatidine-induced junction
potentials (10.960.7 mV in the control; 8.960.7 mV in the
presence of 0.6 mM [Ca
2+]o; P=0.05; Fig. 3Eii). There was a
significant change in EID amplitude distribution in the presence of
0.6 mM [Ca
2+]o (P,0.05, Fig. 3Fiii).
The effect of ryanodine on EID occurrence, EJPs, and
SEJPs
It has previously been shown that nicotine-induced Ca
2+
transients in nerve terminals in the mouse vas deferens depend
on Ca
2+-induced Ca
2+ release (CICR) from intraneuronal Ca
2+
Epibatidine-Induced Neurotransmitter Release
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epibatidine-induced neurotransmitter release, the effect of ryano-
dine on EID generation was investigated. In the presence of
ryanodine, EIDs were significantly altered (Fig. 4A). While the
proportion of responding cells was not significantly different from
controls (proportion control=8267%, proportion cells ryano-
Figure 3. The effect of a,b-Methylene ATP, tetrodotoxin, Cd
2+, or reduced extracellular Ca
2+ concentration on EIDs. Representative
membrane potential traces before and after epibatidine application, in the presence of (A) a,b-MethyleneATP (a,b-MeATP; 1 mM), (B) tetrodotoxin
(TTX; 300 nM), (C) Cd
2+ (100 mM), (D) 0.6 mM extracellular Ca
2+ concentration (0.6 mM [Ca
2+]o), each for 60 minutes. The effect of each treatment on
electrically-evoked neurotransmitter release is shown in the smaller trace in each section. EJPs were evoked by neuronal stimulation at 0.33 Hz. (Ai)
shows EJPs in a representative control trace, (Aii) in the presence of a,b-MeATP, (Bii) TTX, (Cii) CdCl2 (Dii) 0.6 mM [Ca
2+]o. RMPs were between 270
and 280 mV. (E) Quantification of EIDs in the presence of a,b-MeATP, TTX, CdCl2, or 0.6 mM [Ca
2+]o. In each chart, two bars are shown for each
treatment: control epibatidine applications (outline) and epibatidine applications following treatment (filled). Each bar represents the mean 6 s.e.m.
(i) Bar chart showing the mean percentage of cells that responded to epibatidine. (ii) Bar chart of mean EID frequency. (iii) Bar chart of mean EID
amplitude.’’ (F). Cumulative frequency plots of EID amplitude in the presence of (i) TTX, (ii)Cd
2+ (iii) 0.6 mM [Ca
2+]o. All treatments caused a significant
shift of EIDs to smaller amplitudes (P,0.05, Kolmogorov-Smirnov test).
doi:10.1371/journal.pone.0029209.g003
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there was a significant reduction in the frequency of EIDs in the
presence on ryanodine: from 1.4460.08 Hz in the control to
0.9260.09 Hz in the presence of ryanodine (P,0.05; nc
control=30, nc ryanodine=30 nv=5). Surprisingly, the mean
amplitude of EIDs significantly decreased from 10.160.5 mV in
the control, to 6.060.5 mV in the presence of ryanodine
(P,0.05). There was also a large shift in EID amplitude
distribution (P,0.05; Fig. 4B).
The reduction in amplitude of EIDs in the presence of
ryanodine is consistent with either a prejunctional or a
postjunctional effect. To investigate the potential postjunctional
effect of ryanodine and/or the contribution of CICR to low
frequency EJPs, the effect of ryanodine on EJP amplitude was
investigated. As with the previous ryanodine experiments,
preparations were exposed to ryanodine while stimulated (10
stimuli at 10 Hz every 30 s for 60 min). There was no detectable
effect on mean EJP amplitude: following treatment with 10 mM
ryanodine, the amplitude of the first EJP in a pair, 200 ms apart,
evoked at frequency 0.2 Hz was 88.567% of controls (P=0.10,
unpaired Student’s t-test; nc control=36, nc ryanodine=36, nv=6;
Fig. 4C). Previous studies have suggested that, in some
preparations, ryanodine-sensitive Ca
2+ stores may be involved in
facilitation of neurotransmitter release [18]. Ryanodine had no
effect on paired-pulse facilitation of EJP amplitude. In the
presence of ryanodine, paired-pulse facilitation of EJPs was
9862% of the control facilitation (P=0.41, unpaired Student’s t-
test; Fig. 4C).
A postjunctional effect of ryanodine has the potential to change
the time course of decay of the EJP, for example by a direct effect
on the P2X receptor. There was no significant effect of ryanodine
on the time course of repolarisation (decay time constant): the
average time taken for the membrane potential to fall from 90% to
33% (i.e. by about 1/e) of the peak amplitude of an EJP was
3961 ms in the control; in the presence of ryanodine the decay
time was 3662m s( P=0.10, unpaired Student’s t-test).
Ryanodine had no effect on the mean frequency of occurrence
of SEJPs (Fig. 4D). In the presence of ryanodine (60 min), the
frequency of SEJP occurrence was 94613% of the control
(P=0.85). A postjunctional effect of ryanodine would be detected
by a change in the amplitude of SEJPs, but in these experiments
no significant change in amplitude was observed: control
amplitude=4.960.3 mV, ryanodine amplitude=4.560.3
(P=0.29, unpaired Student’s t-test). There was no significant
difference between SEJP amplitude distributions recorded in the
presence and absence of ryanodine (P=0.12; Fig. 4E). These
results indicate that EIDs are partially dependent on CICR,
whereas electrically-evoked neurotransmitter release (at low
frequencies of stimulation) and spontaneous neurotransmitters
release do not involve CICR.
Discussion
This study has shown that rapid application of epibatidine
caused a series of smooth muscle cell depolarisations similar in
appearance to SEJPS that were sensitive to nonselective nAChR
antagonists and blocked following desensitisation of P2X1
receptors. The most plausible explanation for these depolarisations
is that activation of prejunctional nAChRs triggers neurotrans-
mitter (ATP) release from sympathetic nerve terminals. We have
Figure 4. The effect of ryanodine on epibatidine-induced, electrically-evoked, and spontaneous neurotransmitter release. (A) A
typical membrane potential trace showing the effects of epibatidine application following exposure to 10 mM ryanodine for 60 minutes. (B) A
cumulative frequency plot of EID amplitude in the presence of ryanodine. There is a significant shift to smaller EID amplitudes in the presence of
ryanodine (P,0.05, Kolmogorov-Smirnov test. (C) Representative membrane potential trace showing pairs of EJPs evoked by neuronal stimuli 200 ms
apart at a frequency of 0.2 Hz (i) in control recordings and (ii) after ryanodine application for 60 minutes. (D) A representative membrane potential
trace in the absence of neuronal stimulation showing (i) SEJPs in control and (ii) in the presence of ryanodine. (E) A cumulative frequency plot of SEJP
amplitude in the control and in the presence of ryanodine. Ryanodine caused no significant change in SEJP frequency, amplitude, or amplitude
distribution. In all traces, RMPs were between 270 and 280 mV.
doi:10.1371/journal.pone.0029209.g004
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epibatidine causes an increase in neurotransmitter release from
nerve terminals in mouse vasa deferentia [15]. The rapid, local
application method described in the present study enables multiple
recordings of epibatidine-induced response to be made from the
same preparation. This method greatly facilitates the investigation
of the mechanism of epibatidine-induced neurotransmitter release
in the mouse vas deferens.
Epibatidine-induced neurotransmitter release occurred
following activation of non-a7 nAChRs
EIDs could be elicited in the presence of a-BTX or MLA at
concentrations which have previously been demonstrated to block
a7-nAChR-mediated neurotransmitter release [7,19,20]. These
findings suggest that the majority of epibatidine-induced neuro-
transmitter release follows activation of nAChR receptors which
do not contain a7 subunits. Additionally, epibatidine has a
relatively low potency at a7 nAChRs in comparison to other
neuronal nAChRs [21] and given that the actual concentration of
epibatidine that reached the nerve terminals is likely to be
substantially less than 1 mM, it is possible that the concentration of
epibatidine that reaches the nerves terminals will be insufficient to
activate a7-containing nAChRs that may be present.
In the presence of a-BTX and MLA, there was a small shift of
EIDs to lower amplitudes, suggesting that there may be a small
proportion of epibatidine-induced neurotransmitter release that
does depend on a7-nAChR activation. Previous investigations of
nAChR agonist-induced neurotransmitter release have shown
partial sensitivity to a-BTX; for example, in rat vas deferens, a
mixture of a3b4 and a7 nAChRs are expressed [22]. The majority
of epibatidine-induced neurotransmitter release appeared to be
independent of a7-nAChR. A number of other examples of
nAChR agonist-induced neurotransmitter release that are a-BTX
insensitive have been described in other sympathetic neurons [23].
The particular subtype of nAChRs responsible for EID generation
remains to be determined. Of the non-a7 nAChRs present in mouse
sympathetic postganglionic neurons, the vast majority are a3b4,
a3b4a5o ra3b4b2 [24], so it is likely that one of these subtypes is
involved. Other studies have described a role for a5n A C h R si n
neurotransmitter release from axonal sprouts of mouse cultured
superior cervical neurons [25], but speculation on the subtype based
on these results is difficult because of different nAChR subtype
distribution even within the same sympathetic neuron [23,25].
Generation of nerve terminal action potentials is not
required for epibatidine-induced neurotransmitter
release
nAChR-induced TTX-resistant release of neurotransmitter is
well established in cultured sympathetic neurons [23,26,27].
nAChRs are ligand-gated cation channels [28], so an influx of
cations through nAChRs might initiate neuronal action potentials
leading to neurotransmitter release. In the present study, however,
EIDs could still be elicited in the presence of TTX, although there
was a small reduction in their mean amplitude (8364% of the
control). These results suggest that a small proportion of
epibatidine-induced neurotransmitter release depends on action
potential initiation, but most of the neurotransmitter release does
not require functional voltage-gated Na
+ channels (VGSCs).
Previous results from this laboratory have shown a TTX-
insensitive component of epibatidine-induced neurotransmitter
release in contraction studies [15] and demonstrated that nicotine-
induced Ca
2+ transients in nerve terminals in the mouse vas
deferens were unaffected by TTX [14].
The role of VGCCs in epibatidine-induced
neurotransmitter release
The experiments carried out in the presence of Cd
2+ indicate
that most of the epibatidine-induced neurotransmitter release is
independent of VGCC activation. In the present work, the
proportion of Cd
2+-sensitive neurotransmitter release is similar to
the proportion of TTX-sensitive neurotransmitter release (Fig. 3).
Assuming that TTX-sensitive neurotransmitter release requires
VGCC activation, it is likely that the Cd
2+- and TTX-sensitive
release represent the same proportion of epibatidine-induced
neurotransmitter release.
Epibatidine-induced neurotransmitter release is
dependent on extracellular Ca
2+
When [Ca
2+]o was reduced from 1.8 mM to 0.6 mM, there was
a significant reduction in the frequency of occurrence of EIDs. A
small decrease in EID amplitude may be expected in the presence
of reduced [Ca
2+]o, because about 12% of the current through
heterologously expressed P2X1 receptors is carried by Ca
2+ [29],
but the present study was not sufficiently powered to detect this
effect. It has been demonstrated that influx of Ca
2+ through
nAChRs is sufficient to cause an increase in the intraterminal Ca
2+
concentration in this preparation [14].
Intraneuronal Ca
2+ stores and epibatidine-induced
neurotransmitter release
The largest decrease of mean EID amplitude and change of
amplitude distribution was caused by ryanodine. Ryanodine also
decreased the frequency of occurrence to 6464% of the control.
The ryanodine treatment method used here depletes intraneuronal
stores and prevents CICR [30]. Activation of nAChRs can cause
mobilisation of intraneuronal Ca
2+ stores in sympathetic nerves
innervating the mouse vas deferens [14], somatic spines emanating
from chick ciliary ganglion neurones [31] and in SH-SY5Y cells
[32]. Ryanodine-sensitive Ca
2+ stores have also been shown to
have a role in nAChR-induced neurotransmitter release: ryano-
dine reduces action potential-independent nicotine-induced gluta-
mate release [8] and nicotine-induced potentiation of electrically-
evoked glutamate release in rat hippocampus [33]. Previous
studies demonstrating the involvement of intraneuronal Ca
2+
stores in nAChR-induced neurotransmitter release have implicat-
ed the a7 nAChRs, (e.g. [34,35]; see references above).
Interestingly, in our experiments, a7 nAChR did not appear to
have a substantial role in epibatidine-induced neurotransmitter
release. These findings indicate that an alternative, as yet
unidentified, subtype of nAChR can couple to CICR and
neurotransmitter release. Further investigation of the role of these
intraterminal Ca
2+ stores with SERCA inhibitors would be of
great interest.
nAChR activaction may cause multiquantal
neurotransmitter release following mobilisation of
intraterminal Ca
2+ stores
The reduction of the mean amplitude of EIDs may have been
caused by an inhibition of multipacketed release, or near-
synchronous packeted release, from the same varicosity. CICR-
dependent, multiquantal neurotransmitter release following
nAChR activation has been demonstrated in the CA3 region of
the rat hippocampus. Nicotine elicited high amplitude multi-
quantal spontaneous EPSCs which were abolished by ryanodine
and thapsigargin [8]. In the mouse isolated vas deferens, nicotine
and epibatidine induce ryanodine-sensitive Ca
2+ transients in
nerve terminals [14]. It is possible that these nAChR-induced Ca
2+
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2+ transients described by
Llano et al. [36], could result in multivesicular release and be
responsible for the generation of high-amplitude EIDs. An
alternative mechanism is that high-amplitude EIDs may result
from summation of ATP release from several varicosities. Since
ryanodine reduced the overall frequency of occurrence of EIDs,
the probability of stochastic simultaneous occurrences and
therefore the number of high-amplitude EIDs would decrease.
This mechanism appears less likely because at low [Ca
2+]o there is
a greater reduction in EID frequency than with ryanodine
treatment, but low [Ca
2+]o did not significantly affect the mean
EID amplitude.
While there was a clear effect of ryanodine on epibatidine-
induced neurotransmitter release, ryanodine had no significant
effect on electrically-evoked or spontaneous neurotransmitter
release. It is possible that CICR, caused by an influx of Ca
2+
following an action potential, whilst being too slow to influence
neurotransmitter release following that action potential, could
facilitate neurotransmitter release evoked by the next action
potential in a train. In the CNS, the effect of CICR on paired-
pulse facilitation is unclear (see [37]; for a review). In the present
study, ryanodine did not change the degree of potentiation of pairs
of EJPs evoked at 5 Hz. These results are supported by previous
studies in the rodent vas deferens: ryanodine-sensitive neurotrans-
mitter release is only revealed following trains of stimuli at high
frequency (3–50 Hz) in the presence of v-conotoxin GVIA to
block N-type VGCCs [30]; in nerve terminals in the mouse vas
deferens, low frequency action potential-evoked Ca
2+ transients
were not affected by ryanodine [38]. In the present investigation,
ryanodine had no effect on spontaneous neurotransmitter release.
Previous studies in the CNS have shown that most of the
spontaneous neurotransmitter release that is sensitive to ryanodine
is multivesicular or occurs as bursts of neurotransmitter release
[37]. It is possible that this type of spontaneous neurotransmitter
release occurs very infrequently in the mouse vas deferens and
could not be detected in present experiments.
The tissue location of nAChRs
While a number of different cell types are present in the mouse
vas deferens, including a small number of cholinergic nerve
terminals which also contain prejunctional nAChRs [39], the
insensitivity of EIDs to TTX/Cd
2+, the highly local agonist
application and the rapid onset of neurotransmitter release, all
suggest that the nAChRs responsible for the observed neurotrans-
mitter release are located directly on the sympathetic nerve
terminals. Despite this, we are unable to rule out rapid signaling to
sympathetic terminals from nicotinic receptors located on nearby
cells.
Of the cells monitored, 24% did not respond to epibatidine.
Care was taken to record from cells positioned close to the surface
of the vas deferens, adjacent to the pipette. Unfortunately, it was
not possible to determine accurately the position of the impaled
cell and some recordings were likely to have been obtained from
cells located deeper within the tissue. Given the small volume of
epibatidine applied and the transient nature of its application, it is
possible the lack of response was caused by an insufficient
concentration of epibatidine reaching nerve terminals that
innervated these cells. Bath application of 100 nM epibatidine
causes robust and reliable neurotransmitter release [15], which
indicates that in the ‘non-responders’ in current study, the
concentration of epibatidine at the nerve terminals was likely to
be substantially less than 100 nM. Variability in the epibatidine
concentration that reaches the nerve terminals may also be
responsible for the variability in the size of the epibatidine-induced
response. The alternative hypothesis, that terminals possess
differing numbers of nAChRs, cannot be ruled out.
Physiological and pathophysiological relevance of
nAChRs on sympathetic nerve terminals
Given that the vast majority of sympathetic postganglionic
neurons do not use acetylcholine as a transmitter, the physiological
function of prejunctional nicotinic receptors remains unclear and
may only rarely be functionally important. While it is true that
sympathetic and parasympathetic axons and terminals can run in
close proximity within the peripheral organs (for an example in the
mouse vas deferens, see [40]), the common presence of inhibitory
muscarinic receptors on sympathetic nerve terminals [41], which
have a much higher affinity for acetylcholine, implies that only
exposure to high local concentrations of acetylcholine are likely to
produce a nicotinic excitatory response that is sufficient to oppose
the muscarinic inhibition. It is also possible that the sympathetic
nerves are sensitive to local non-neuronal acetylcholine sources
[42]. Given that only provisional reports link endogenous
acetylcholine release (acting at prejunctional nicotinic receptors)
to an increased release of noradrenaline from sympathetic
terminals [43], at present the most important implications for
the current study are in the peripheral response to drugs and as a
model system for understanding nerve terminal Ca
2+ regulation in
the context of nicotinic receptor activation.
Nicotine’s actions on sympathetic nerve terminals contribute to
its acute cardiovascular effects [4,44,45], and may also play a role
in sympathetic innervation of the urogenital tract. For example,
acute nicotine exposure (nicotine gum) reduces erectile function
without affecting subjective sexual arousal [46], which points
towards a peripheral amplification of sympathetic drive, noting
that sympathetic drive to the penis is associated with flaccidity.
Central nervous system presynaptic nicotinic receptors remain
key targets for pharmacological approaches to dementias,
although the currently available drugs have produced only
marginal clinical improvements [47]; hence, understanding
tractable models of nicotinic receptor function is useful for drug
development.
In summary, this study describes a nAChR-induced neuro-
transmitter release of which the majority is independent of
neuronal action potential generation and does not require
VGCCs. The most likely mechanism is a combination of influx
of Ca
2+ through nAChRs and CICR from ryanodine-sensitive
intraneuronal Ca
2+ stores. The unidentified nAChR subtype
responsible for this neurotransmitter release is one of the first
descriptions of a non-a7 nAChR that can couple to CICR and
subsequent neurotransmitter release.
Supporting Information
Figure S1 Time courses of SEJP and EID. Representative
membrane trace of an EID (black line) and a SEJP (thick grey line)
obtained from the same recording 10 s before epibatidine
application (SEJP) and 3 s after epibatidine application (EID).
The amplitude of the SEJP and EID were normalized to facilitate
comparison of the time courses.
(TIF)
Figure S2 Variable responses to epibatidine applica-
tion. Membrane potential traces from three different cells (A–C)
before and after 1 mM epibatidine application. The time of
epibatidine application is indicated by an arrow. Resting
membrane potentials were 270 to 280 mV.
(TIF)
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in the presence of various drugs. Each point represents the
mean frequency of SEJP/EID occurrence collected in 2 s bins.
The error bars represent the s.e.m. Only data from responding
cells are included. Control recordings are shown in blue and
recordings in the presence of a drug are shown in red. A) Time
control (nc control=29, nc time control=30, nv=6). B) 100 nM a-
bungarotoxin (a-BTX; nc control=30, nc a-BTX=31, nv=5). C)
20 nM methyllacaconitine (MLA; nc control=30, nc MLA=30,
nv=5). D) 300 nM tetrodotoxin (TTX;, nc control=29, nc
TTX=31, nv=6). E) 100 mMC d
2+ (nc control=28, nc
Cd
2+=30, nv=5). F) 0.6 mM extracellular Ca
2+ (0.6 mM
[Ca
2+]o; nc control=30, nc 0.6 mM [Ca
2+]o, nv=5). G) 10 mM
ryanodine (nc control=30, nc ryanodine=30, nv=5).
(TIF)
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